Cairns R - Search Results

1

Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.

Doehner W, Erdmann E, Cairns R, Clark AL, Dormandy JA, Ferrannini E, Anker SD. Doehner W, et al. Among authors: cairns r. Int J Cardiol. 2012 Dec 15;162(1):20-6. doi: 10.1016/j.ijcard.2011.09.039. Epub 2011 Oct 29. Int J Cardiol. 2012. PMID: 22037349 Clinical Trial.

2

A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study.

Pfister R, Cairns R, Erdmann E, Schneider CA. Pfister R, et al. Among authors: cairns r. Int J Cardiol. 2013 Jan 10;162(2):112-6. doi: 10.1016/j.ijcard.2011.05.056. Epub 2011 Jun 1. Int J Cardiol. 2013. PMID: 21636144 Clinical Trial.

3

Incidence of new onset bundle branch block and atrial fibrillation in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study.

Pfister R, Michels G, Cairns R, Schneider CA, Erdmann E. Pfister R, et al. Among authors: cairns r. Int J Cardiol. 2011 Dec 1;153(2):233-4. doi: 10.1016/j.ijcard.2011.09.049. Epub 2011 Oct 9. Int J Cardiol. 2011. PMID: 21985750 Clinical Trial. No abstract available.

4

Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study.

Pfister R, Cairns R, Erdmann E, Schneider CA; PROactive investigators. Pfister R, et al. Among authors: cairns r. Diabet Med. 2011 Oct;28(10):1206-12. doi: 10.1111/j.1464-5491.2011.03281.x. Diabet Med. 2011. PMID: 21388447

5

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.

Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators. Ray KK, et al. Among authors: cairns r. J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10. doi: 10.1016/j.jacc.2005.03.077. J Am Coll Cardiol. 2005. PMID: 16226162 Clinical Trial.

6

Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Ray KK, et al. Among authors: cairns r. Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):424-30. doi: 10.1161/ATVBAHA.108.181735. Epub 2009 Jan 2. Arterioscler Thromb Vasc Biol. 2009. PMID: 19122170 Clinical Trial.

7

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators. Wiviott SD, et al. Among authors: cairns r. Circulation. 2007 Dec 18;116(25):2923-32. doi: 10.1161/CIRCULATIONAHA.107.740324. Epub 2007 Dec 3. Circulation. 2007. PMID: 18056526 Clinical Trial.

8

Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS.

Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, Gibson CM; PROVE IT-TIMI 22 Investigators. Ray KK, et al. Among authors: cairns r. Eur Heart J. 2006 Oct;27(19):2310-6. doi: 10.1093/eurheartj/ehl180. Epub 2006 Aug 3. Eur Heart J. 2006. PMID: 16887854 Clinical Trial.

9

Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.

Mega JL, Morrow DA, Cannon CP, Murphy S, Cairns R, Ridker PM, Braunwald E. Mega JL, et al. Among authors: cairns r. J Thromb Thrombolysis. 2006 Aug;22(1):71-6. doi: 10.1007/s11239-006-8081-0. J Thromb Thrombolysis. 2006. PMID: 16786236 Clinical Trial.

10

Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.

Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E; PROVE IT-TIMI 22 Investigators. Ray KK, et al. Among authors: cairns r. J Am Coll Cardiol. 2005 Oct 18;46(8):1417-24. doi: 10.1016/j.jacc.2005.08.024. J Am Coll Cardiol. 2005. PMID: 16226164 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results